



To: Cold Stored Platelet Program Hospitals
From: Hospital Relations
Date: August 6, 2021
Re: Cold Stored Platelets Program Enrollment – 2nd notice

Background

Carter BloodCare is pleased to announce that the variance to collect, process and distribute cold stored platelets with a 14 day storage has been approved by the FDA. Carter BloodCare plans to distribute these products effective **September 27, 2021**. As we move closer to implementing 14 day cold stored platelets, this is your second notice that **your facility will be automatically enrolled in the cold-stored platelets program**. Facilities that are being automatically enrolled maintain one or more apheresis platelets on-site, but have a historical usage percentage of approximately 30%.

Client Action

- Update laboratory and/or blood bank information systems to accept the ISBT product codes associated with cold-stored apheresis platelets.
- Review and update policies associated with platelet storage and indications for use. If your facility stores more than 1 platelet on-site, prepare policies for maintaining a dual inventory.
- Inform laboratory medical directors and clinicians of the anticipated new component and its indications for use. Additional information regarding the use of cold stored platelets is attached for medical director and clinician review.

Cold stored apheresis platelets

- Store the apheresis platelet products at refrigerated temperatures (1-6°C).
- Store up to 14 days without agitation.
- Bacterial detection testing is not required.
- Platelets are approved for the treatment of actively bleeding patients through day 14 of storage or when conventional platelet products are unavailable or their use is not practical.
- Eligible for return/re-stock on scheduled rotation day(s).
- Product cost remains the same as the 7 day room temperature apheresis platelets.